Boston Scientific stock falls after 2026 guidance cut
Published on 09/08/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock fell after Boston Scientific Corporation (ISIN US10117L1017) said on September 8, 2026 that it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts. Reuters reported that the warning followed a cybersecurity incident that disrupted global operations.
Guidance turns lower
The company had guided in July for 2026 adjusted earnings of $3.28 to $3.32 per share and reported sales growth of 5.5 percent to 6.5 percent, while third-quarter adjusted earnings were projected at 80 cents to 82 cents per share. Reuters The new warning is a clear numerical change in tone: full-year sales growth and earnings guidance have both been put at risk after the cyberattack.
That matters because Wall Street had been looking for full-year adjusted earnings of $3.30 per share on revenue of $21.35 billion, according to the same market coverage cited on September 8, 2026. Blockonomi The gap between the prior company range and those external expectations now frames the stock's next move.
Restoration is the key
Boston Scientific said major distribution centers were processing and shipping products at or above normal levels in an update that Investing.com highlighted on September 8, 2026. TD Cowen kept a Buy rating and a $56 price target, while other houses trimmed targets after the second-quarter results and the first cyberattack disclosure. Investing.com
The quantified contrast is sharp: TD Cowen's $56 target sits above the premarket reference around $46.68 reported in the same coverage, implying the market is still trading well below that level. Blockonomi For investors, the next read-through is whether restored shipping and manufacturing can narrow the guidance gap before the company updates its outlook again.
Watch the product mix
Boston Scientific's statement leaves the product mix in focus, especially franchises tied to global distribution and elective procedure demand. Reuters said the company had already been tracking toward 2026 adjusted earnings of $3.28 to $3.32 per share before the cyber incident changed the outlook on September 8, 2026. Reuters
Stock level
Boston Scientific stock was quoted at $46.68 in premarket trading on September 8, 2026 in the cited market coverage, after a 4.6 percent decline to $45.60 was also reported earlier the same day. Blockonomi
Boston Scientific stock at a glance
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Trading venue: NYSE
- Price (as of September 8, 2026): USD 46.68
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
